Bain Capital Life Sciences Investors, LLC
CIK:0001703031
Private Equity
$676M AUM
23 holdings
Boston, MA, USA
Bain Capital Life Sciences Investors, LLC partners with life science companies globally, focusing on innovation in pharmaceuticals, biotechnology, medical devices, diagnostics, and life science tools to address unmet medical needs. The firm invests across four primary opportunity types: inflection capital, growth capital, fallen angels, and larger private equity collaborations/new company formation.
Investment Strategy
Targets investments in biopharmaceutical, medical device, diagnostic, and life science tool companies. Focuses on inflection points, growth stages, turnaround ('fallen angel') opportunities, and collaborative or co-creation private equity deals.
Top Buys
C
CDTXCIDARA THERAPEUTICS INC+$106.7M
U
UPBUPSTREAM BIO INC+$12.7M
C
CABACABALETTA BIO INC+$10.9M
T
TNGXTANGO THERAPEUTICS INC+$10.2M
S
SLDBSOLID BIOSCIENCES INC+$9.3M
Top Sells
N
NAMSNEWAMSTERDAM PHARMA COMPANY-$25.3M
I
IRONDISC MEDICINE INC-$17.9M
S
SVRASAVARA INC-$8.6M
X
XFORX4 PHARMACEUTICALS INC-$4.0M
D
DNTHDIANTHUS THERAPEUTICS INC-$2.5M
Top Holdings
N
NAMSNEWAMSTERDAM PHARMA COMPANY+24.3%$194.1M
C
CDTXCIDARA THERAPEUTICS INC+15.2%$121.8M
N
NUVLNUVALENT INC+13.8%$110.4M
P
PHVSPHARVARIS N V+7.3%$58.1M
D
DNTHDIANTHUS THERAPEUTICS INC+5.8%$46.2M
Equity Positions (22)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
N NAMS | NEWAMSTERDAM PHARMA COMPANY | 24.29% | $194.1M | 10,719,110 | $11.44 | $18.11 | -$25.3M |
C CDTX | CIDARA THERAPEUTICS INC | 15.24% | $121.8M | 2,500,680 | $38.04 | $48.71 | +$106.7M |
N NUVL | NUVALENT INC | 13.82% | $110.4M | 1,447,267 | $22.85 | $76.30 | +$7.8M |
P PHVS | PHARVARIS N V | 7.27% | $58.1M | 3,303,381 | $23.53 | $17.60 | +$6.3M |
D DNTH | DIANTHUS THERAPEUTICS INC | 5.79% | $46.2M | 2,482,250 | $29.71 | $18.63 | -$2.5M |
Industry Allocation
PHARMACEUTICAL PREPARATIONS
+72.2%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+24.1%
BLANK CHECKS
+3.9%
LABORATORY ANALYTICAL INSTRUMENTS
+3.6%